Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

A number of other research analysts have also weighed in on the company. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Performance

TVRD stock opened at $3.93 on Friday. The stock has a market capitalization of $36.86 million, a P/E ratio of -0.41 and a beta of 0.14. Tvardi Therapeutics has a one year low of $3.50 and a one year high of $43.65. The company has a 50 day moving average price of $4.08 and a two-hundred day moving average price of $12.32.

Hedge Funds Weigh In On Tvardi Therapeutics

Large investors have recently bought and sold shares of the stock. Slate Path Capital LP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $16,427,000. American Financial Group Inc. purchased a new position in shares of Tvardi Therapeutics in the 4th quarter worth $962,000. 683 Capital Management LLC acquired a new position in Tvardi Therapeutics in the second quarter valued at $4,107,000. Vestal Point Capital LP acquired a new position in Tvardi Therapeutics in the third quarter valued at $6,508,000. Finally, Geode Capital Management LLC purchased a new stake in Tvardi Therapeutics during the second quarter valued at about $2,617,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.